Innate immunity in Alzheimer's disease

Nature Immunology

Volumn 16, Issue 3, 2015, Pages 229-236

  Heneka, Michael T ^a,b,c   Golenbock, Douglas T ^a,b,c   Latz, Eicke ^a,b,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CELL DEATH; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; LONG TERM POTENTIATION; MEDIATOR; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION;

EID: 84923444904     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3102     Document Type: Review

References (89)

1. Jack C.R. Jr., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013).
2. Querfurth H.W. & LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010).
3. Bertram L., Lill C.M. & Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281 (2010).
4. Mawuenyega K.G., et al. Decreased clearance of CNS b-amyloid in Alzheimer's disease. Science 330, 1774-1774 (2010).
5. Walsh D.M., et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
6. Hammer N.D., Schmidt J.C. & Chapman M.R. The curli nucleator protein CsgB contains an amyloidogenic domain that directs CsgA polymerization. Proc. Natl. Acad. Sci. USA 104, 12494-12499 (2007).
7. Chapman M.R., et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295, 851-855 (2002).
8. Epstein E.A. & Chapman M.R. Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres. Cell. Microbiol. 10, 1413-1420 (2008).
9. Monje M.L., Toda H. & Palmer T.D. Inflammatory blockade restores adult hippocam-pal neurogenesis. Science 302, 1760-1765 (2003).
10. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
11. Sastre M., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amy-loid precursor protein through regulation of b-secretase. J. Neurosci. 23, 9796-9804 (2003).
12. In t' Veld B.A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521 (2001) .
13. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47, 401-411 (1996).
14. Cagnin A., et al. In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467 (2001).
15. Yasuno F., et al. Increased binding of peripheral benzodiazepine receptor in mild cogni-tive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106. Psychiatry Res. 203, 67-74 (2012).
16. Lambert J.-C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099 (2009).
17. Karch C.M., Cruchaga C. & Goate A.M. Alzheimer's disease genetics: from the bench to the clinic. Neuron 83, 11-26 (2014).
18. Liu S., et al. TLR2 is a primary receptor for Alzheimer's amyloid b peptide to trigger neuroinflammatory activation. J. Immunol. 188, 1098-1107 (2012).
19. Stewart C.R., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161 (2010).
20. Lim J.-E., et al. MyD88 deficiency ameliorates b-amyloidosis in an animal model of Alzheimer's disease. Am. J. Pathol. 179, 1095-1103 (2011).
21. Lim J.-E., et al. The effects of MyD88 deficiency on exploratory activity anxiety motor coordination and spatial learning in C57BL/6 and APPswe/PS1dE9 mice. Behav. Brain Res. 227, 36-42 (2012).
22. Reed-Geaghan E.G., Savage J.C., Hise A.G. & Landreth G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar Ab-stimulated microglial activation. J. Neurosci. 29, 11982-11992 (2009).
23. Maezawa I., Zimin P.I., Wulff H. & Jin L.-W. Amyloid-b protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J. Biol. Chem. 286, 3693-3706 (2011).
24. Wright A.L., et al. Neuroinflammation and neuronal loss precede Ab plaque deposi-tion in the hAPP-J20 mouse model of Alzheimer's disease. PLoS ONE 8, e59586 (2013).
25. Heneka M.T., et al. Focal glial activation coincides with increased BACE1 activa-tion and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflammation 2, 22 (2005).
26. Sojkova J. & Resnick S.M. In vivo human amyloid imaging. Curr. Alzheimer Res. 8, 366-372 (2011).
27. Davalos D., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752-758 (2005).
28. El Khoury J., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 432-438 (2007).
29. Cribbs D.H., et al. Extensive innate immune gene activation accompanies brain aging increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflammation 9, 179 (2012).
30. Latz E., Xiao T.S. & Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397-411 (2013).
31. Halle A., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-b. Nat. Immunol. 9, 857-865 (2008).
32. Tong L., et al. Brain-derived neurotrophic factor-dependent synaptic plasticity is sup-pressed by interleukin-1b via p38 mitogen-activated protein kinase. J. Neurosci. 32, 17714-17724 (2012).
33. Youm Y.-H., et al. Canonical Nlrp3 inflammasome links systemic low-grade inflamma-tion to functional decline in aging. Cell Metab. 18, 519-532 (2013).
34. Heneka M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678 (2013).
35. Cameron B., et al. Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. J. Neurosci. 32, 15112-15123 (2012
36. Vom Berg J., et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18, 1812-1819 (2012).
37. Terwel D., et al. Critical role of astroglial apolipoprotein E and liver X receptor-a expres-sion for microglial Ab phagocytosis. J. Neurosci. 31, 7049-7059 (2011).
38. Vodovotz Y., et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184, 1425-1433 (1996).
39. Hoshino T., et al. Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice. J. Neurosci. 31, 5225-5234 (2011).
40. Paolicelli R.C., et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456-1458 (2011).
41. Yirmiya R. & Goshen I. Immune modulation of learning memory neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181-213 (2011).
42. Lynch M.A. Neuroinflammatory changes negatively impact on LTP: A focus on IL-1b. Brain Res. 10.1016/j.brainres.2014.08.040 (2014).
43. Pickering M., Cumiskey D. & O'Connor J.J. Actions of TNF-a on glutamatergic syn-aptic transmission in the central nervous system. Exp. Physiol. 90, 663-670 (2005).
44. Cumiskey D., Pickering M. & O'Connor J.J. Interleukin-18 mediated inhibition of LTP in the rat dentate gyrus is attenuated in the presence of mGluR antagonists. Neurosci. Lett. 412, 206-210 (2007).
45. Wang Q., Rowan M.J. & Anwyl R. b-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimu-lation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24, 6049-6056 (2004).
46. Bachstetter A.D., et al. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. J. Neurosci. 32, 10201-10210 (2012).
47. Lee M., et al. Acidic fibroblast growth factor (FGF) potentiates glial-mediated neuro-toxicity by activating FGFR2 IIIb protein. J. Biol. Chem. 286, 41230-41245 (2011).
48. Cho S.-H., et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 286, 32713-32722 (2011).
49. Neniskyte U., Neher J.J. & Brown G.C. Neuronal death induced by nanomolar amyloid b is mediated by primary phagocytosis of neurons by microglia. J. Biol. Chem. 286, 39904-39913 (2011).
50. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N. & LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853 (2005).
51. Lee C.Y. & Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 117, 949-960 (2010).
52. Bhaskar K., et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19-31 (2010).
53. Sy, M., et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am. J. Pathol. 178, 2811-2822 (2011).
54. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (2007).
55. Gorlovoy P., Larionov S., Pham T.T.H. & Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 23, 2502-2513 (2009).
56. Ghosh S., et al. Sustained interleukin-1b overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J. Neurosci. 33, 5053-5064 (2013).
57. Heneka M.T., et al. Locus ceruleus controls Alzheimer's disease pathology by modu-lating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. USA 107, 6058-6063 (2010).
58. Kummer M.P., et al. Mrp14 deficiency ameliorates amyloid b burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. J. Neurosci. 32, 17824-17829 (2012).
59. Grommes C., et al. Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J. Neuroimmune Pharmacol. 3, 130-140 (2008).
60. Zhu Y., et al. CD45 deficiency drives amyloid-b peptide oligomers and neuronal loss in Alzheimer's disease mice. J. Neurosci. 31, 1355-1365 (2011).
61. Yuyama K., Sun H., Mitsutake S. & Igarashi Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-b by microglia. J. Biol. Chem. 287, 10977- 10989 (2012).
62. Hollingworth P., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011).
63. Liang Y. & Tedder T.F. Identification of a CD20-, FceRIb-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 72, 119-127 (2001).
64. Lajaunias F., Dayer J.-M. & Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 35, 243-251 (2005).
65. Bradshaw E.M., et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848-850 (2013).
66. Griciuc A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid b. Neuron 78, 631-643 (2013).
67. Melchior B., et al. Dual induction of TREM2 and tolerance-related transcript Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2, e00037 (2010).
68. Frank S., et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56, 1438-1447 (2008
69. Hamerman J.A., et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177, 2051-2055 (2006).
70. Bouchon A., Hernández-Munain C., Cella M. & Colonna M.A. DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 194, 1111-1122 (2001).
71. Takata K., et al. Galantamine-induced amyloid-b clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J. Biol. Chem. 285, 40180-40191 (2010).
72. Mandrekar-Colucci S., Karlo J.C. & Landreth G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-g-mediated amyloid clearance and rever-sal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 32, 10117-10128 (2012).
73. Yamanaka M., et al. PPARg/RXRa-induced and CD36-mediated microglial amyloid-b phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 32, 17321-17331 (2012).
74. Adolfsson R., Gottfries C.G., Roos B.E. & Winblad B. Changes in the brain catechol-amines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135, 216-223 (1979).
75. Leissring M.A., et al. Enhanced proteolysis of b-amyloid in APP transgenic mice prevents plaque formation secondary pathology and premature death. Neuron 40, 1087-1093 (2003).
76. Tamboli I.Y., et al. Statins promote the degradation of extracellular amyloid b-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J. Biol. Chem. 285, 37405-37414 (2010).
77. Kumar S., et al. Phosphorylation of amyloid-b peptide at serine 8 attenuates its clear-ance via insulin-degrading and angiotensin-converting enzymes. J. Biol. Chem. 287, 8641-8651 (2012
78. Sheng J.G., et al. Lipopolysaccharide-induced-neuroinflammation increases intracel-lular accumulation of amyloid precursor protein and amyloid b peptide in APPswe transgenic mice. Neurobiol. Dis. 14, 133-145 (2003).
79. Weberpals M., et al. NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J. Neurosci. 29, 14177-14184 (2009).
80. Lemstra A.W., et al. Microglia activation in sepsis: a case-control study. J. Neuroinflammation 4, 4 (2007).
81. Holmes C., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774 (2009).
82. Iwashyna T.J., Ely E.W., Smith D.M. & Langa K.M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. J. Am. Med. Assoc. 304, 1787-1794 (2010).
83. Semmler A., et al. Persistent cognitive impairment hippocampal atrophy and EEG changes in sepsis survivors. J. Neurol. Neurosurg. Psychiatry 84, 62-69 (2013).
84. Kamer A.R., et al. TNF-a and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. J. Neuroimmunol. 216, 92-97 (2009).
85. Kamer A.R., et al. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement. 4, 242-250 (2008).
86. Lumeng C.N., Bodzin J.L. & Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007).
87. Uryu K., et al. Repetitive mild brain trauma accelerates Ab deposition lipid peroxida-tion and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22, 446-454 (2002).
88. Stalder M., et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154, 1673-1684 (1999).
89. Simard A.R., Soulet D., Gowing G., Julien J.-P. & Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's dis-ease. Neuron 49, 489-502 (2006